TYLOGRAN, 1000 mg/g, гранули за употреба във вода за пиене/мляко за говеда (телета), свине, пилета и пуйки 1 g/1.1 g гранули Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

tylogran, 1000 mg/g, гранули за употреба във вода за пиене/мляко за говеда (телета), свине, пилета и пуйки 1 g/1.1 g гранули

dopharma b.v. - Тилозин - гранули - 1 g/1.1 g - говеда, морски свинчета, пилета, пуйки

ENDOMETROX aerosolum spumescens 45 g аерозол Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

endometrox aerosolum spumescens 45 g аерозол

ВЕТПРОМ АД - Тилозин, Нитроксолин Има - аерозол - 750 000 iu/45 g; 0, 75 g/45 g - кобили

NEOTYL syringae intramammariae Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

neotyl syringae intramammariae

ВЕТПРОМ АД - Тилозин; неомицина сулфат - интрамамарна маз - 250 000 iu (0, 29 g)/10 g; 100 000 iu (0, 15 g)/10 g - говеда, кози, овце

TYLJET 200 mg/ml инжекционен разтвор за говеда, овце, кози и свине 200 mg/ml Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

tyljet 200 mg/ml инжекционен разтвор за говеда, овце, кози и свине 200 mg/ml

Сева Анимал Хелт България ЕООД - Тилозин - Инжекционен разтвор - 200 mg/ml - говеда, кози, овце, свине

TYLO 200 WSP 200 mg/g Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

tylo 200 wsp 200 mg/g

kepro b.v. - Тилозин (като тартрат) - прах за прилагане във водата за пиене/мляко или млекозаместител - 200 mg/g - прасета, птици, телета

TYLOFARM WATER SOLUBLE POWDER Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

tylofarm water soluble powder

ФАРМА ВЕТ ООД - Тилозин тартрат - прах за прилагане във вода за пиене - 40 000 000 iu (50 g) - птици, свине

TYLOVET B -200 solution for injection for cattle, sheep, goats, swine and dogs 200 mg/ml Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

tylovet b -200 solution for injection for cattle, sheep, goats, swine and dogs 200 mg/ml

Биовет АД - Тилозин - инжекционен разтвор - 200 mg/ml - говеда, кози, кучета, овце, свине

TYLOVET pulvis water soluble powder for chickens, turkeys, pigs and calves 500 mg/g Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

tylovet pulvis water soluble powder for chickens, turkeys, pigs and calves 500 mg/g

Биовет АД - Тилозин (като tartarate) - прах за прилагане във вода за пиене/мляко - 500 mg/g - пилета, прасета, пуйки, телета

Opdivo União Europeia - búlgaro - EMA (European Medicines Agency)

opdivo

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Антинеопластични средства - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

ТИЛОВЕТ ФОРТЕ ВОДОРАЗТВОРИМИ ГРАНУЛИ ЗА ПТИЦИ гранули Bulgária - búlgaro - БАБХ (Българска агенция по безопасност на храните)

ТИЛОВЕТ ФОРТЕ ВОДОРАЗТВОРИМИ ГРАНУЛИ ЗА ПТИЦИ гранули

Биовет АД - Тилозин тартрат (еквивалент на тилозина база); Бромгексина хидрохлорид - гранули - 333 mg/g; 6.6 mg/g - бройлери, ПСН, пуйки